Christopher Posner's most recent trade in Tvardi Therapeutics Inc. was a trade of 583 Common Stock done at an average price of $4.7 . Disclosure was reported to the exchange on Feb. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 28 Feb 2025 | 583 | 13,109 (0%) | 0% | 4.7 | 2,769 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 4.72 per share. | 04 Feb 2025 | 372 | 13,692 (0%) | 0% | 4.7 | 1,756 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 0.29 per share. | 04 Nov 2024 | 3,668 | 168,768 (0%) | 0% | 0.3 | 1,064 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 0.35 per share. | 01 Aug 2024 | 4,149 | 172,436 (0%) | 0% | 0.3 | 1,452 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 0.75 per share. | 02 May 2024 | 3,936 | 176,585 (0%) | 0% | 0.8 | 2,952 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 29 Feb 2024 | 5,834 | 180,521 (0%) | 0% | 0.9 | 5,192 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 0.53 per share. | 08 Feb 2024 | 35,575 | 186,355 (0%) | 0% | 0.5 | 18,855 | Common Stock |
| Tvardi Therapeutics Inc | A. Posner Christopher | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 62,500 | 226,911 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc | A. Posner Christopher | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 01 Feb 2024 | 4,981 | 221,930 (0%) | 0% | 0.6 | 2,740 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.40 per share. | 05 May 2023 | 3,869 | 172,514 (0%) | 0% | 4.4 | 17,024 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.71 per share. | 03 Mar 2023 | 5,987 | 176,383 (0%) | 0% | 9.7 | 58,134 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.80 per share. | 02 Feb 2023 | 4,191 | 182,370 (0%) | 0% | 11.8 | 49,454 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.13 per share. | 16 Nov 2022 | 14,470 | 186,561 (0%) | 0% | 11.1 | 161,051 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.67 per share. | 04 Apr 2022 | 2,006 | 201,031 (0%) | 0% | 12.7 | 25,416 | Common Stock |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 121,000 | 121,000 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc | Christopher A. Posner | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 39,000 | 203,037 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc | Christopher Posner | Director, Senior Advisor | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2021 | 566,000 | 566,000 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc | Christopher Posner | Director, Senior Advisor | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2021 | 142,000 | 164,037 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc | Christopher Posner | Director, Senior Advisor | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2021 | 5,941 | 22,037 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc | Christopher Posner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 10,800 | 10,800 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc | Christopher Posner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 7,200 | 18,400 (0%) | 0% | 0 | Common Stock | |
| Tvardi Therapeutics Inc | Christopher Posner | Director | Sale of securities on an exchange or to another person at price $ 13.04 per share. | 03 Jun 2021 | 2,304 | 16,096 (0%) | 0% | 13.0 | 30,044 | Common Stock |
| Tvardi Therapeutics Inc | Christopher Posner | Director | Sale of securities on an exchange or to another person at price $ 15.82 per share. | 19 Nov 2020 | 2,000 | 11,200 (0%) | 0% | 15.8 | 31,638 | Common Stock |